Updated Sep. 3, 2014 at 7:52 a.m.

Xellia Pharma commits to $100M investment, 40 new jobs in Raleigh

Published: 2014-09-03 07:47:00
Updated: 2014-09-03 07:52:27

Jobs  Jobs

Lured in part by property tax incentives from the City of Raleigh, Xellia Pharmaceuticals will invest $100 million in the expansion of its manufacturing plant and create 40 new full-time jobs.

Xellia purchased a manufacturing plant run by Fresenius Kabi in July.

Under the agreement, Xellia will receive a 50 percent "pgrant" based on paid property taxes to the City of Raleigh over five years once a "minimal" investment of $100 million investment is made.

The company also agreed to create 40 "permanent full-time jobs" over the next five years. Average annual salaries are to range from $45,000 to $70,000.

Additionally, the company must retain 90 existing jobs.

“When it came to establishing our first U.S. manufacturing facility earlier this year, our priority was to locate close to a prominent bioscience cluster and a specialized pharmaceutical skills base, so Raleigh was a natural choice," said Carl-Ake Carlsson, Xellia's chief executive officer, in a statement. "We are very pleased to be able to use this incentive to expand the site and to attract the most talented and productive employees to grow the team here further. We would like to thank the City of Raleigh for its consideration and approval of our application which we hope will help to drive economic growth in this area.”

The details

The full announcement follows: 

The City of Raleigh is providing a business incentives grant to Xellia Pharmaceuticals for the expansion of its manufacturing facility located at 8900 Capital Boulevard. The grant is a performance based incentive and requires the company to create 40 permanent full-time jobs within the next five years with average annual salaries of $45,000 to $70,000 and the retention of 90 existing jobs.

Xellia plans to combine the incentive from the City of Raleigh with its own investment to hire people across a wide spectrum of roles from manufacturing technicians and maintenance mechanics to senior quality control and assurance, validation and technology transfer specialists.

The grant also requires Xellia to make a minimal new property tax investment of $100,000,000. This grant will allocate 50 percent of paid property taxes to Xellia Pharmaceuticals on a yearly basis for five years.

Carl-Åke Carlsson, CEO of Xellia Pharmaceuticals said: “When it came to establishing our first U.S. manufacturing facility earlier this year, our priority was to locate close to a prominent bioscience cluster and a specialized pharmaceutical skills base, so Raleigh was a natural choice. We are very pleased to be able to use this incentive to expand the site and to attract the most talented and productive employees to grow the team here further. We would like to thank the City of Raleigh for its consideration and approval of our application which we hope will help to drive economic growth in this area.”

Some key facts:

 

  • · In July, Xellia Pharmaceuticals acquired the dedicated freeze-dried vial manufacturing facility in Raleigh from Fresenius Kabi.
  • · Xellia has more than 100 years of pharmaceutical industry experience and specializes in difficult-to-manufacture and develop anti-infective products.
  • · These products are supplied to more than 500 pharmaceutical companies in 70 countries around the world.
  • · The company employs more than 1,000 people and has research and development, manufacturing and commercial sites in eight countries
  • · Xellia is wholly owned by Novo A/S which owns other companies with facilities in this area including Novo Nordisk and NovoZymes.
  • · Prospective employees can find out more about the range of roles and opportunities available at Xellia’s Raleigh site on the careers page at www.xellia.comor by contacting Barbara.Porch@xellia.com.


 

WRAL TechWire any time: Twitter, Facebook

Copyright 2014 WRAL TechWire. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Best of TechWire Insider

Techwire Inside Partners

OUR INSIDERS

Dr. Mike Walden
Tech economy
Vivek Wadhwa
Commentary
Frank Vinluan
Life science
Scroll